Close

Spanish regulators give manufacturing license to Midatech Biogune

Related stories

New Syngene biologics manufacturing facility to be operational for US and European customers from mid-year

At DCAT 2024 global bio/pharmaceutical manufacturing forum, Syngene International,...

ST Pharm breaks ground on 2nd oligonucleotide manufacturing plant

ST Pharm said it has taken its first step...

Elevating Biopharmaceutical Projects With The Right CDMO

In the biopharma industry, selecting the right contract development...

Biovian announces over €50 million investment in manufacturing facility in Turku, Finland

Biovian, a leading contract development and manufacturing organization (CDMO)...

New PAT – Based Strategy Stops Membrane Fouling In SP – TFF

A recent article published in the Journal of Membrane...

The Spanish Medicines Agency has given Investigational Medicinal Products (IMP) License to Midatech Biogune to manufacture clinical grade nanoparticles at its Bilbao manufacturing facility, Spain.
Prior to licensing the manufacturing facility, the Spanish Medicines Agency has conducted inspection on 15 and 16 February 2011.Midatech claims its biocompatible nanoparticles possess a number of properties that make them ideal for diagnostic and therapeutic applications.

Their small size potentially enables drug delivery via different routes of administration, including parental, transdermal, mucosal, intradermal, transbuccal, sublingual or intranasal/inhalation.Midatech Biogune CEO Justin Barry said getting such a positive response from the Medicines Agency validates the quality of their manufacturing and endorses the investment that Midatech has made into its first class quality systems.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories